Recursion Pharmaceuticals Bolsa (NASDAQ: RXRX)

Últimas noticias sobre Recursion Pharmaceuticals (NASDAQ:RXRX) Bolsa

Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

News

Offerings

Contracts

AIXI

XIAO-I Entered Into Two Securities Purchase Agreements To Issue, Sell Two Convertible Promissory Notes Of $4.6M

Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) just disclosed its Q1 earnings on Friday, January 10, 2025 at 02:19 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Lexaria Bioscience missed estimated earnings by -33.0%, reporting an EPS of $-0.16 versus an estimate of $-0.12.
Revenue was up $32 thousand from the same period last year.
<h3>Earnings History Overview</h3>
During the previous quarter, the company missed on EPS by $0.04, leading to a 2.0% drop share price change the next day.

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Lexaria Bioscience <a href="https://www.benzinga.com/quote/LEXX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

LEXX

Lexaria Bioscience Earnings Analysis: Q1 Recap

Accolade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) released its Q3 earnings on Friday, January 10, 2025 at 09:30 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Accolade missed estimated earnings by -87.0%, reporting an EPS of $-0.3 versus an estimate of $-0.16.
Revenue was up $5.69 million from the same period last year.
<h3>Historical Earnings Summary</h3>
Last quarter the company beat on EPS by $0.14 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Accolade's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.44</td>
<td>-0.48</td>
<td>-0.07</td>
<td>-0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.30</td>
<td>-0.35</td>
<td>-0.10</td>
<td>-0.28</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>105.01M</td>
<td>105.19M</td>
<td>123.91M</td>
<td>96.24M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>106.36M</td>
<td>110.47M</td>
<td>124.83M</td>
<td>99.37M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accolade <a href="https://www.benzinga.com/quote/ACCD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCD

Accolade Q3 Earnings Assessment

Electric vehicle company Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) was one of the many companies that presented or showed off new products, concepts and company growth initiatives at the<a href="https://www.benzinga.com/25/01/42775636/ces-2025-preview-nvidia-amd-in-spotlight-other-trends-and-stocks-to-watch"> 2025 CES conference.</a>
An electric vehicle media outlet is skeptical of the company's latest plan for growth.
What Happened: When it comes to Faraday Future, the company has focused on the premium <a href="https://www.benzinga.com/electric-vehicles">electric vehicles sector</a> with the FF 91 having a cost of more than $300,000.
The company now plans to grow with its new Faraday X sub-brand and have vehicles priced in the $20,000 to $50,000, executives told <a href="https://insideevs.com/news/746781/faraday-x-ceo-interview/">InsideEVs </a>at CES.
Faraday plans to have the FX 5 and FX 6 vehicles priced from $20,000 to $30,000 and $30,000 to $50,000 respectively and the Super One minivan with a current undetermined price as the next models for growth.
A Super One prototype was at CES and Faraday X CEO Max Ma highlighted the company's excitement for this luxury passenger van.
Ma called the vehicle the "Nokia and iPhone moment" for Faraday Future saying, "You have the right product and open people's hearts."
Ma said the Super One will serve the market between high-end minivans and super-luxury SUVs, adding that it will transform the market.
"Today, the celebrities are using Escalades. Big, but there's no real luxury, top luxury, or you know, space and comfort. There's no AI. And then if you want to drive yourself, it's very hard to drive," Ma told InsideEVs.
Focusing on growth through AI, Ma also referred to the Super One as a "luxury AI MPV."
The prototype shown to the media highlighted the fact that Faraday has partnered with a Chinese company to make the Super One.
"Essentially, the Super One will be a rebadged Chinese plug-in hybrid MPV, with FF's tech," InsideEVs said.
The writer said the vehicle looked simply like a Chinese MPV and had no AI features.
Read Also: <a href="https://www.benzinga.com/news/small-cap/25/01/42893897/faraday-futures-fx-6-to-target-30k-50k-price-range-with-ai-driven-ev-tech-details">Faraday Future&#8217;s FX 6 To Target $30K-$50K Price Range With AI-Driven EV Tech</a>
Why It's Important: Faraday Future has struggled since announcing <a href="https://www.benzinga.com/m-a/21/01/19367501/faraday-future-going-public-via-spac-what-investors-should-know">a SPAC merger back </a>in 2021.
The merger announcement came with a value of $3.4 billion for the company. Fast forward to today and Faraday Future has a market capitalization of $94 million and an enterprise value of $203 million.
Shares are down 92% over the last year and down 43% year-to-date in 2025 already.
The appearance and prototype at CES could help restore brand awareness and trust in the company after several controversies and failures along the way. Top of Form
"We have been trained, with big hearts, with resilience, with hard (work). We also want to have this big opportunity to prove that we can do it again, right?" Ma told InsideEVs.
Ma noted the company is looking for a fresh start of sorts, which Faraday X could be the centerpiece of.
The CES presentation and media interview could cause some confusion with the company highlighting its focus on cheaper electric vehicles and showing off and naming a luxury multi-person vehicle as growth items.
FFIE Price Action: Faraday Future stock trades at $1.56 at market close Friday versus a 52-week trading range of $0.99 to $155.60.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41541997/revving-up-in-the-middle-east-faradays-new-uae-headquarters-solidifies-ev-expansion-strategy">Revving Up In The Middle East: Faraday&#8217;s New UAE Headquarters Solidifies EV Expansion Strategy</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Global

Tech

Trading Ideas

FFIE

Faraday Future Highlights Faraday X: Here's What The EV Company Is Banking On After Stock Fell 90% In Past Year

BLKB

Blackbaud Files For Mixed Shelf Offering; Size Not Disclosed

Wall Street wiped out its entire post-election rally this week as mounting interest-rate fears were stoked by a red-hot labor market, surging inflation expectations and escalating geopolitical tensions ahead of Donald Trump&#8216;s <a href="https://www.benzinga.com/news/25/01/42916780/donald-trump-receives-unconditional-discharge-in-new-york-hush-money-case-will-enter-white-house-as-convicted-felon">return to the White House</a>. 
In a shortened trading week due to Thursday&#8217;s funeral for former President Jimmy Carter, market activity reached a<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42922299/wall-street-tumbles-on-blowout-payrolls-oil-rallies-to-76-us-dollar-hits-26-month-highs-whats-driving-markets-friday"> fever pitch on Friday.</a>
The U.S. economy boasted an impressive <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">256,000 nonfarm payrolls</a> in December — a figure that made the consensus economist forecast of 160,000 jobs pale in comparison. This marked the strongest employment growth since March. Additionally, the unemployment rate dropped to 4.1%, beating forecasts of 4.2%.
In simple terms, the U.S. labor market ended 2024 firing on all cylinders. While this robust performance bodes well for consumer spending, it poses a significant challenge for the Federal Reserve, which now faces mounting pressure to <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42913622/dollar-soars-to-27-month-highs-30-year-yields-hit-5-stocks-tumble-jobs-report-oil-spike-darken-feds-interest-rate-cut-hopes">keep inflation in check.</a>
Expectations for a new interest rate cut were further pushed down the road to September 2025 in reactions to new economic developments. For stocks, this represented a setback, as indices tumbled across the board.
Earlier in the week, President-elect Trump, in a one-hour speech at Mar-a-Lago, floated provocative ideas, including annexing <a href="https://www.benzinga.com/news/events/25/01/42860583/trump-floats-canada-as-51st-us-state-says-hes-ready-to-use-economic-force-to-achieve-it">Canada as a 51st state</a>, imposing stringent tariffs on Mexico and demanding NATO members increase military spending to 5% of GDP.
On Friday, the Biden administration announced <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/42919047/oil-nears-80-as-us-prepares-new-russia-sanctions">new sanctions targeting Russian oil </a>giants Gazprom Neft and Surgutneftegas, shadow fleet vessels and opaque traders. These measures triggered a sharp rise in oil prices, further unsettling markets.
<h3 class="wp-block-heading">Inflation Fears Surge</h3>
Consumer inflation expectations for the next five years reached 3.3% in January 2025, hitting their highest levels since June 2008, according to <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42917321/consumer-inflation-worries-highest-since-2008-u-of-m-survey-says-wall-street-tumbles-to-2-month-lows">a University of Michigan survey</a>. Rising inflation anxiety may reflect concerns over the incoming Trump administration&#8217;s planned tariff hikes.
<h3 class="wp-block-heading">Wildfires Impact Insurers</h3>
California wildfires destroyed over 10,000 structures, intensifying pressure on property insurers like Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) and Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>). Economic losses could reach $57 billion, with insurance <a href="https://www.benzinga.com/markets/equities/25/01/42906089/california-wildfires-ignite-concerns-for-insurance-stocks-here-are-some-insurance-etfs-which-could-be-impacted">stocks under market focus.</a>
<h3 class="wp-block-heading">Rate Hike Panic</h3>
The blowout December jobs report forced Bank of America Securities to scrap expectations for further interest-rate cuts. It marks a notable U-turn from a top investment bank. Economist Aditya Bhave floated the risk of rising discussions towards interest rate cuts, should core inflation <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42926956/bank-of-america-scraps-interest-rate-cut-calls-betting-markets-go-haywire-as-hiking-panic-mounts">surges above 3% again. </a>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42925767/palantirs-nasdaq-100-hype-fades-as-stock-sinks-post-inclusion">Palantir&#8217;s Nasdaq-100 Hype Fades As Stock Sinks 15% Post-Inclusion</a></li>
</ul>
Image: Shutterstock

Analyst Color

Government

Large Cap

Macro Economic Events

Regulations

Economics

Federal Reserve

US Labor Market Smashes Expectations, Wall Street Erases Post-Election Rally As Interest Rate Anxiety Grows: This Week In The Markets

Raytech Holding Limited (the "Company" or "RAY"), a Hong Kong-headquartered company specializing in design, sourcing and wholesale of personal care electrical appliances for international brand owners, today announced its financial results for the six months ended September 30, 2024.
CHING Tim Hoi, CEO and Chairman of the Company, commented, "The Company achieved a notable 31.0% increase in revenue for the six months ended September 30, 2024, reaching HKD 43.2 million (US$ 5.6 million), up from HKD 33.0 million in the prior year. This growth was driven primarily by strong sales in our trimmer series within the personal care products segment, reflecting our success in attracting new customers."

Raytech 6-Month EPS $0.03; Revenue $5.56M

SYSTEM1 Announced Today That It Was Notified By The New York Stock Exchange That It Is Not In Compliance; Company Intends To Cure The Deficiency And Regain Compliance With NYSE

Boqii Holding Limited ("Boqii" or the "Company") (NYSE American:&nbsp;BQ) today announced that it will change its ratio of its American Depositary Shares ("ADSs") to Class A ordinary shares from one (1) ADS representing fifteen (15) Class A ordinary shares to one ADS&nbsp;representing one hundred and fifty&nbsp;(150) Class A ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on or about January 21, 2025&nbsp;(U.S. Eastern Time) (the "ADS Ratio Change&nbsp;Effective Date").
For Boqii's ADS holders, the ADS Ratio Change will have the same effect as a 1-for-10 reverse split on the&nbsp;existing ADSs. Each ADS holder on the ADS Ratio Change Effective Date will be required on mandatory basis to surrender to The Bank of New York Mellon, as depositary, (the "Depositary") for Boqii's ADS program, every 10 old ADSs held in exchange for one new&nbsp;ADSs. No action is required by holders of&nbsp;uncertificated ADSs to effect the ADS Ratio Change as the change will be effected on the books of the Depositary.&nbsp;&nbsp;

Stock Split

Boqii Announces ADS Ratio Change From 1 ADS Representing 15 Class A Ordinary Shares To 1 ADS Representing 150 Class A Ordinary Shares, Effective On Or About January 21, 2025

Politics

General

President Biden To Deliver Farewell Address From Oval Office On Wednesday At 8:30 p.m. ET

HTLF

UMBF

UMB Financial Corp Receives Regulatory Approval To Acquire Heartland Financial USA

Rexford Industrial Realty, Inc. (the "Company" or "Rexford Industrial") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>), a real estate investment trust focused on creating value by investing in and operating industrial properties located throughout infill Southern California,&nbsp;today reports no damage to its properties and does not anticipate unfavorable impacts to the Company's operating results or financial condition due to the wildfires in Los Angeles County.

REXR

Rexford Industrial Reports No Impacts To Business From The Wildfires In Los Angeles County

Management

VRDN

Viridian Therapeutics Appoints Seth Harmon As CFO

VTAK

Catheter Precision Files For Mixed Shelf Of Up To $20M

MCHX

Marchex Terminates CFO Holly Aglio's Employment; Says Brian Nagle Appointed Principal Financial And Accounting Officer

Scotts Miracle-Gro Files For Mixed Shelf; Size Not Disclosed

Occidental Petroleum Says Average Realized Prices For Total Worldwide Natural Gas For Three Months Ended Dec 31, $1.41/MCF; Average Realized Prices For Total Worldwide Oil For Three Months Ended Dec 31 Is $69.73/BBL

<a href="https://news.delta.com/atl-runways-begin-reopen-after-weather-challenges-operations-worlds-largest-hub" title="https://news.delta.com/atl-runways-begin-reopen-after-weather-challenges-operations-worlds-largest-hub">https://news.delta.com/atl-runways-begin-reopen-after-weather-challenges-operations-worlds-largest-hub</a>

Delta Air Lines Says ATL Runways Begin To Reopen After Weather Challenges Operations At World's Largest Hub; Canceled ~700 Flights Across Our Network For Friday, Jan. 10

<ul>
<li>Initial loan proceeds of $782 million expected to be funded this month and balance of proceeds funded through planned construction period</li>
<li>DOE loan guarantee facilitates expansion of Sustainable Aviation Fuel capacity to 300 million gallons per year</li>
</ul>
INDIANAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) ("Calumet," "we," "our" or "us") announced today the closing of a $1.44 billion guaranteed loan facility with the U.S. Department of Energy ("DOE") Loan Programs Office ("LPO"). The loan will fund the construction and expansion of the renewable fuels facility owned by Montana Renewables, LLC ("Montana Renewables" or "MRL"), an unrestricted subsidiary of Calumet.
The expansion positions Montana Renewables as one of the largest Sustainable Aviation Fuel ("SAF") producers globally, enabling an increase in annual production capacity to approximately 300 million gallons of SAF and 330 million gallons of combined SAF and renewable diesel ("RD"). The planned expansion includes several key components: a second renewable fuels reactor (allowing approximately half of the 300-million-gallon SAF capability to be online by 2026), debottlenecking of existing units, installation of SAF blending and logistics assets, increased renewable hydrogen production, cogeneration for renewable electricity and steam, and on-site water treatment and recycling capabilities.

Financing

CLMT

Montana Renewables Announces Closing Of $1.44B DOE Loan Facility For Renewable Fuels And Biomass Energy Facility

Kohl's To Cut Jobs; Kohl's To Close San Bernardino E-Commerce Fulfillment Center When Lease Ends In May, And 27 Underperforming Stores By April; Kohl's Expects Pretax Charges Of About $60M-$80M; San Bernardino EFC Is One Of 15 In Its Nationwide Supply Chain Network; Reaffirms 2024 Financial And Capital Allocation Outlook Excluding Charges

Recursion Pharmaceuticals (RXRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Alec S...

Cautious Optimism for Recursion Pharmaceuticals Amid Promising Safety Profile and Upcoming Milestones

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report). The company...

TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)

In a report released today, Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report), with a price targe...

Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Iambic Therapeutics appoints Michael Secora, as chief corporate development officer and CFO

Recursion announced that the UK Medicines and Healthcare Products Regulatory Agency has cleared a clinical trial application for a Phase 1 clinical...

Recursion announces two oncology drugs advancing to clinical trials

Among the various use-cases for AI, healthcare has been one of the interesting ones. Recursion Pharmaceuticals (RXRX) is one such notable player in the industry that has successfully leveraged AI in drug discovery.

AI Drug Discovery Stocks: Recursion Pharmaceuticals Has A Long Road Ahead

KeyBanc lowered the firm's price target on Recursion Pharmaceuticals (RXRX) to $10 from $12 and keeps an Overweight rating on the shares. The firm ...

Recursion Pharmaceuticals price target lowered to $10 from $12 at KeyBanc

20:02 EST Cathie Wood's ARK Investment buys 653K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 653K shares of Recursion Pharmaceuticals today

Recursion: Investors Will Need To Be Patient

RXRX

Health Care

Press Releases

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That's Expected to be a $7.2 Billion Market by 2029

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Small Cap

Opinion

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Comments

Recursion Pharmaceuticals

Noticias

Últimas noticias sobre Recursion Pharmaceuticals (NASDAQ:RXRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL